<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02810756</url>
  </required_header>
  <id_info>
    <org_study_id>N16PZN</org_study_id>
    <nct_id>NCT02810756</nct_id>
  </id_info>
  <brief_title>Study With Improved Solubility Pazopanib</brief_title>
  <official_title>Proof of Principle and Pharmacological Phase 0 Study With Improved Solubility Pazopanib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The pharmacokinetics of a new formulation with Pazopanib will be studied. This will be done&#xD;
      in a patient cohort of n = 12.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 15, 2016</start_date>
  <completion_date type="Actual">August 28, 2017</completion_date>
  <primary_completion_date type="Actual">August 28, 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration</measure>
    <time_frame>24 hours</time_frame>
    <description>Concentration of pazopanib in plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>1 week</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>24 hours</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Pharmacokinetics of Pazopanib</condition>
  <arm_group>
    <arm_group_label>Treated patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>New Pazopanib formulation</intervention_name>
    <arm_group_label>Treated patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Locally advanced or metastatic cancer;&#xD;
&#xD;
          -  Able and willing to give written consent;&#xD;
&#xD;
          -  WHO performance status of 0, 1 or 2;&#xD;
&#xD;
          -  Able and willing to undergo blood sampling for PK analysis;&#xD;
&#xD;
          -  Minimal acceptable safety laboratory values;&#xD;
&#xD;
          -  Negative pregnancy test for female patients with childbearing potential;&#xD;
&#xD;
          -  Able and willing to swallow oral medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any treatment with investigational drugs within 30 days prior to receiving the&#xD;
             investigational treatment;&#xD;
&#xD;
          -  Any treatment with CYP3A4, BCRP or PGP interfering drugs;&#xD;
&#xD;
          -  Patients who received treatment with Votrient(R) kess than 1 week ago;&#xD;
&#xD;
          -  Woman who are pregnant or breast feeding;&#xD;
&#xD;
          -  Patients suffering from any known condition that may influence the dissolution or&#xD;
             absorption of Pazopanib.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Netherlands Cancer Institute</name>
      <address>
        <city>Amsterdam</city>
        <state>North Holland</state>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>May 31, 2016</study_first_submitted>
  <study_first_submitted_qc>June 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2016</study_first_posted>
  <last_update_submitted>September 8, 2017</last_update_submitted>
  <last_update_submitted_qc>September 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data will remain confidential</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

